Bevirimat: a novel maturation inhibitor for the treatment of HIV-1 infection. - Wikidata - wikimedia - TriplyDB

Bevirimat: a novel maturation inhibitor for the treatment of HIV-1 infection.

Bevirimat: a novel maturation inhibitor for the treatment of HIV-1 infection.

http://www.wikidata.org/entity/Q34885660

about

In vitro selection of clinically relevant bevirimat resistance mutations revealed by "deep" sequencing of serially passaged, quasispecies-containing recombinant HIV-1 A single polymorphism in HIV-1 subtype C SP1 is sufficient to confer natural resistance to the maturation inhibitor bevirimat HIV type 1 Gag as a target for antiviral therapy Pharmacological intervention of HIV-1 maturation Structural and functional insights into the HIV-1 maturation inhibitor binding pocket Mechanistic Studies and Modeling Reveal the Origin of Differential Inhibition of Gag Polymorphic Viruses by HIV-1 Maturation Inhibitors Role of the SP2 domain and its proteolytic cleavage in HIV-1 structural maturation and infectivity The capsid protein of human immunodeficiency virus: designing inhibitors of capsid assembly.The Second-Generation Maturation Inhibitor GSK3532795 Maintains Potent Activity Toward HIV Protease Inhibitor-Resistant Clinical Isolates Novel approaches to inhibiting HIV-1 replication.Polymorphisms in Gag spacer peptide 1 confer varying levels of resistance to the HIV- 1 maturation inhibitor bevirimat Identification and Characterization of BMS-955176, a Second-Generation HIV-1 Maturation Inhibitor with Improved Potency, Antiviral Spectrum, and Gag Polymorphic Coverage.HIV-1 Capsid Inhibitors as Antiretroviral Agents Discovery of BMS-955176, a Second Generation HIV-1 Maturation Inhibitor with Broad Spectrum Antiviral Activity.Betulinic acid derivatives as human immunodeficiency virus type 2 (HIV-2) inhibitors.Recent advances in anti-HIV natural products.Conserved Interaction of Lentiviral Vif Molecules with HIV-1 Gag and Differential Effects of Species-Specific Vif on Virus Production.Anti-retroviral drugs: current state and development in the next decade.The KT Jeang Retrovirology prize 2018: Eric Freed.

P2860

Q24599377-BF5A67F6-5D66-4A4F-A9F3-1D2D2578D830 Q24606079-63502242-34F2-4B97-A018-4527F819C10F Q24614498-90CB6F3F-625A-430A-A8F9-93C6CB683AB2 Q26771739-31163BBF-D645-48FF-8FA1-DC55A76149EA Q28485054-4DC0D286-3EB7-48EE-A15F-5825BD0DCBE7 Q28554482-0B55C78D-E78A-483E-93E5-30FB27C24EFE Q28710568-DC841E0D-0C62-427E-B492-7B7877352860 Q33510254-9531C761-1267-4D26-A951-35017B313F67 Q33557807-73E3D594-D22C-4219-B42C-1F5CCE114DDD Q33624690-411BF661-7631-4DA7-8305-2762F6EA275D Q33864444-7C1D14CA-565C-428C-A250-C82A50EEAD9B Q35992805-ADD6AFEE-60E7-4F92-B66A-A22FC0960622 Q36672006-CA187673-440B-4921-9A8B-BF28EF142288 Q36996295-26B239E6-9D50-4C49-B946-F0CFA819FDE4 Q37459163-7E669DC4-728B-49C6-9F39-E190941DD897 Q37803138-858115FC-546A-47CB-9536-9D653BB67B55 Q38765818-ABE85F10-6D35-4A3C-A42E-00F93A6EADCF Q54222874-E3135F6E-5A34-4E71-9DAE-E2309C51F99A Q55517077-D1B12590-CB5B-4786-9E9B-CA49E3BB74F0

P2860

Bevirimat: a novel maturation inhibitor for the treatment of HIV-1 infection.

http://www.wikidata.org/entity/Q34885660

description

2008 nî lūn-bûn

@nan

2008 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Bevirimat: a novel maturation inhibitor for the treatment of HIV-1 infection.

@ast

Bevirimat: a novel maturation inhibitor for the treatment of HIV-1 infection.

@en

Bevirimat: a novel maturation inhibitor for the treatment of HIV-1 infection.

@nl

type

label

Bevirimat: a novel maturation inhibitor for the treatment of HIV-1 infection.

@ast

Bevirimat: a novel maturation inhibitor for the treatment of HIV-1 infection.

@en

Bevirimat: a novel maturation inhibitor for the treatment of HIV-1 infection.

@nl

prefLabel

Bevirimat: a novel maturation inhibitor for the treatment of HIV-1 infection.

@ast

Bevirimat: a novel maturation inhibitor for the treatment of HIV-1 infection.

@en

Bevirimat: a novel maturation inhibitor for the treatment of HIV-1 infection.

@nl

P1433

Q34885660-B88EB6BF-7622-4CD2-A18C-F483ABC1228A

P1476

Q34885660-96472F3F-28CA-477E-8FD2-89D34D5E905A

P2093

Q34885660-38CDF0A3-E116-4286-81B2-97F1DC81A94D

Q34885660-C30559B1-B7D1-4804-A248-45F4D1CD690D

Q34885660-CF88CCB4-48A6-4FCA-847E-4CD31D997BCA

P2860

Q34885660-050CA03B-0709-4410-BC56-0C3993A1B340

Q34885660-0727CAD0-BA29-434F-85C8-167FE6D014BE

Q34885660-09AF2D5F-ADF4-480B-9499-1F2A6C48DB67

Q34885660-0E2CC76F-7672-4321-943B-9C971A20BB7C

Q34885660-10440ACE-E93B-49CF-A359-ADDD5CBF2BAE

Q34885660-19F11D9E-843C-4622-B69E-1C51911788C1

Q34885660-1B11EC3B-87AF-4D9B-A0BB-B0E14D2C4B0B

Q34885660-1EC4778E-8815-462C-A8B8-71FC818A34B9

Q34885660-1F5D2CF9-0676-4E71-A5F4-5BB534294136

Q34885660-24C733AB-2E96-4BC2-8DA8-C72C81E5CFFD

P304

Q34885660-481C9597-86EF-440A-AE0E-304E06EDEA6E

P31

Q34885660-774DF7F0-AC86-44F7-93BB-D882EF0F61E3

P356

Q34885660-73DE1BFB-154D-482A-A951-DEDE4B77D525

P433

Q34885660-86F6F542-D6D5-4377-A358-A2ECEB67E0AA

P478

Q34885660-D68C8D0E-14C0-48B0-96AF-6E4C4325DE1E

P577

Q34885660-6E288859-FBA2-4DC3-A254-72081F77A878

P5875

Q34885660-57ECF1EF-B76D-4338-B2EF-5C920707D02A

P698

Q34885660-7A8497A0-A1E3-4D2F-AF57-D4CD1C4D09ED

P921

Q34885660-3032777D-55F7-4FFC-911A-A541C0ADA8B2

P356

095632020801900301

P1433

Antiviral Chemistry & Chemotherapy

P1476

Bevirimat: a novel maturation inhibitor for the treatment of HIV-1 infection.

@en

P2093

David E Martin

http://www.w3.org/2001/XMLSchema#string

Graham P Allaway

http://www.w3.org/2001/XMLSchema#string

Karl Salzwedel

http://www.w3.org/2001/XMLSchema#string

P2860

Potent activity of the HIV-1 maturation inhibitor bevirimat in SCID-hu Thy/Liv mice

Phase I and II study of the safety, virologic effect, and pharmacokinetics/pharmacodynamics of single-dose 3-o-(3',3'-dimethylsuccinyl)betulinic acid (bevirimat) against human immunodeficiency virus infection

Safety and pharmacokinetics of Bevirimat (PA-457), a novel inhibitor of human immunodeficiency virus maturation, in healthy volunteers

The sequence of the CA-SP1 junction accounts for the differential sensitivity of HIV-1 and SIV to the small molecule maturation inhibitor 3-O-{3',3'-dimethylsuccinyl}-betulinic acid

AIDS: is there an answer to the global pandemic? The immune system in HIV infection and control.

Multiple-dose pharmacokinetics and safety of bevirimat, a novel inhibitor of HIV maturation, in healthy volunteers.

HIV drug development: the next 25 years.

In vitro resistance to the human immunodeficiency virus type 1 maturation inhibitor PA-457 (Bevirimat).

Treatment of antiretroviral-drug-resistant HIV-1 infection.

Highly active antiretroviral therapy: current state of the art, new agents and their pharmacological interactions useful for improving therapeutic outcome.

P304

107-113

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/095632020801900301

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

19

http://www.w3.org/2001/XMLSchema#string

P577

2008-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23488600

http://www.w3.org/2001/XMLSchema#string

P698

19024627

http://www.w3.org/2001/XMLSchema#string

P921